Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an antiangiogenic effect. It refers to regular administration of low doses of cytotoxic drugs, with minimal or no drug-free breaks. Previously, we demonstrated the immunomodulating activity of a single low-dose of cyclophosphamide (Cy) and the antitumor effect of MCT with Cy on established rat lymphomas and sarcomas. Here, we examined whether the immune response is responsible for the antitumor effect of MCT with Cy on L-TACB lymphoma. Inbred e rats and nude mice were subcutaneously challenged with L-TACB. After 7 days, they were distributed into two experimental groups: 1) treated animals, which were injected IP with Cy (10 mg/kg body weight) three times per week, and 2) control animals, which received IP saline injections. Exponential growth and decay and tumor doubling time were calculated. Also, serum IL-10 levels were measured. One hundred percent of treated rats showed tumor regression versus 0% of control rats. The increase of tumor-induced IL-10 levels was reverted by the treatment with Cy. On the other hand, there were no tumor regressions, in treated or control nude mice. However, the tumor doubling times of treated nude mice were significantly higher than those of control mice, implying that other antitumor mechanism(s), independent of the adaptive immune response, might be taking place. Our present results indicate that modulation of the immune response would be involved in the antitumor effect of MCT with Cy, because the absence of the specific immune response impairs, at least in part, its therapeutic effect in a lymphoma tumor model.
INTRODUCTION
apy (100% and 83% complete tumor regression, respectively), that does not cause loss of weight and is devoid of hematological, cardiac, hepatic, and renal toxicity (7). Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment. It refers to regular Preclinical and clinical experiments have shown that the therapeutic effect of MCT is achieved through inhibition administration of comparatively low doses of cytotoxic drugs, with minimal or no drug-free breaks, over proof angiogenesis (1,8,9). Our objective here was to investigate whether the immune response is also responsible longed periods of time (1). We have previously demonstrated that a single low dose of cyclophosphamide (Cy), for the antitumor effect obtained with metronomic administration of Cy in a rat lymphoma model. a treatment completely devoid of toxicity, inhibits the growth of spontaneous and experimental metastasis of a rat lymphoma, while it does not affect primary tumor MATERIALS AND METHODS growth (2). Such an effect would be mainly due to modAnimals ulation of the immune response (3-6). We also demonstrated that administration of Cy at low doses on a thrice Inbred adult female IIM e/Fm rats (10) from the Facultad de Ciencias Médicas, Universidad Nacional de weekly schedule, with no rest periods, to established rat lymphomas and sarcomas is a successful antitumor therRosario breeding facilities and N:NIH (S)-nu nude mice 602 ROZADOS ET AL.
from Universidad Nacional de La Plata breeding facili-(days), and 0.69/k = doubling time. Goodness of fit was quantified by the coefficient of determination (R 2 ), and ties were used for these study. The animals were fed with commercial chow and water ad libitum, and were also judged by the convergent on a solution and the significance of a runs test performed to verify the random maintained in a 12-h light/dark cycle. All the experiments were done during the first half of the light cycle distribution of the residuals. For statistical analysis, doubling time was treated as a new random variable and and in accordance with animal care standards of the institution, which complies with the guidelines issued by differences between groups were analyzed with the nonparametric Mann-Whitney U-test. the Canadian Council on Animal Care.
All the statistical tests were done with the GraphPad Prism version 3.0 (GraphPad Software, San Diego, Cyclophosphamide CA, USA). Differences were considered to be statistiCyclophosphamide (Cy) was obtained from Laboracally significant at p < 0.05. torio Filaxis, SA, Argentina. It was dissolved in sterile distilled water to a concentration of 20 mg/ml.
RESULTS AND DISCUSSION

Tumor
The antiangiogenic mechanism of action of MCT, be it normalization of tumor vasculature, inhibition of reLymphoma L-TACB is a poorly differentiated B-cell lymphoma, which arose spontaneously in an inbred e rat population of tumor cells, or amplification of the antivascular effects of chemotherapy (12), is nowadays (11) and it is maintained by in vivo periodic challenge in syngeneic rats.
widely accepted. Nevertheless, other mechanisms may well contribute to the therapeutic effect of MCT, mainly depending on the chemotherapeutic agent administered.
Experimental Model
Cyclophosphamide is the alkylating agent most comAdult e rats and nude mice were subcutaneously chalmonly used in cancer chemotherapy and one of the first lenged with L-TACB by trocar (day 0). When tumors cytotoxic drugs employed in metronomic chemotherapy were detectable (day 7), animals were distributed as fol- (13) . While high doses of Cy [i.e. maximum tolerated lows: treated rats-e rats (n = 6) were injected IP with dose (MTD)] cause immunosuppression, a single low Cy (10 mg/kg body weight) three times per week, from dose has an immunomodulatory effect (4,5,14,15). Thus, day 7; control rats-e rats (n = 6) were injected IP with our question was if the regular administration of low saline three times per week, from day 7; treated micedoses of Cy would cause stimulation of the antitumor nude mice (n = 7) treated the same as treated rats; conimmune response like a single low dose does, or would trol mice-nude mice (n = 7) treated the same as control induce its suppression, like Cy when it is administered rats. Tumors were measured twice weekly and tumor in the MTD. Hence, we examined whether the therapeuvolumes were calculated as follows: V = 0.4 (ab 2 ), tic effect obtained when low doses of Cy are adminiswhere V = volume (mm 3 ), a = largest diameter (mm), tered with no significant breaks in tumor-bearing aniand b = smallest diameter (mm). The experiments ended mals involves the adaptive immune response. on day 19 (rats) or day 17 (nude mice), or when animals Cross-species comparisons have been consistently reached the maximum permitted tumor volume. Blood used to evaluate the efficacy of different antitumor treatsamples, taken from the tail vein of e rats, were colments in an environment devoid of specific immune relected on day 0 (basal level, before tumor inoculation) sponse. Therefore, we developed syngeneic and xenogeand at the end of the experiments, and were stored at neic models in which euthymic rats and athymic nude −20°C until used. IL-10 serum levels were measured by mice were challenged with L-TACB. The treated groups a sandwich ELISA assay (OptEIA TM , BD Biosciences received low dose Cy in a metronomic schedule, beginPharmingen, San Diego, CA, USA), in duplicate.
ning the treatment on day 7, when tumors reached a mean volume of 520 and 460 mm 3 in rats and nude Statistics mice, respectively. After a short period of tumor growth that lasted until day 12, 100% of treated rats showed Exponential growth and decay were calculated applying an exponential regression curve and one-phase exposustained tumor regression (Fig. 1A, inset) versus 0% of control rats (Fig. 1B) . We analyzed the exponential nential decay curve, respectively. For tumor volume doubling time (TvDT), a nonlinear estimation procedure growth and decay of the treated (Fig. 1A , left and right, respectively) and control rat tumors (Fig. 1B) . We found was used to fit the experimental individual tumor volume-time data, set with an exponential model: V(t) = that during the growing phase, TvDT (tumor volume doubling time) was higher (slower growth rate) in Start.exp (k.t), where V(t) = tumor volume at time t, Start = tumor volume at time 0, k = constant, t = time treated rats than in control rats and the difference was marginally significant (p = 0.057) (Fig. 1C) . This outimmunopotentiation induced by treatment of tumorbearing rats with a single low-dose Cy is mainly medicome emphasized the early tumor response to metronomic chemotherapy.
ated by a reduction in T-cell-derived IL-10 production (5). Accordingly, we measured IL-10 serum levels in LInterestingly, neither treated ( Fig. 2A) nor control nude mice (Fig. 2B) showed signs of tumor regression.
TACB-bearing rats treated with Cy in an MCT schedule. As shown in Figure 3 , IL-10 levels in control rats inThe contrasting response in treated rats and mice suggests the involvement of the adaptive immune response creased significantly with tumor progression (ANOVA, p = 0.0124; basal versus control: Tukey-Kramer, p < in the antitumor effect of MCT with Cy in the L-TACB tumor model. We have previously demonstrated in the 0.01). However, the levels of IL-10 in MTC-treated tumor-bearing rats did not differ from basal levels. same model that the shift from immunosuppression to sponse when administered in a metronomic fashion. This mechanism could be exploited therapeutically in order to increase the efficacy of the treatment. The clinical efficacy obtained with metronomic low-dose cyclophosphamide therapy in a patient with an advanced mucosa-associated lymphoid tissue lymphoma (19) underlines the importance of improving this therapeutic modality. Also it suggests the necessity of studying the relationship between other drugs usually employed in metronomic schedules and the immune system.
In summary, MCT with cyclophosphamide, a therapeutic modality that was initially thought as mainly anti- cally, TvDT of tumors from treated nude mice was significantly higher (p = 0.002) than that of control mice REFERENCES (Fig. 2C) . Because nude mice have an impaired immune
